ALFC Double Feature - Making Lateral Flow Accessible Everywhere

·29 min·2 clips

Otomo validated its technology in Africa with low-literacy cohorts and picture-only IFUs.

1. cc: Life Science Podcast uses this ALFC double feature to compare Otomo Diagnostics and EaseBio around lateral flow testing. 2. Chris Conner hosts the conversation and introduces John Kelly from Otomo Diagnostics and Ying Chen from EaseBio, who are both tied to the Advanced Lateral Flow Conference in San Diego. 3. The episode asks how lateral flow tests can become easier to use without losing reliability in home and field settings. 4. John Kelly says Otomo has spent more than 10 years improving usability and reliability in point-of-care rapid testing. 5. Kelly describes laboratory-developed assays that use calibrated equipment and trained staff, then contrasts them with decentralized settings where cheap accessories and limited training create errors. 6. Otomo validated its technology in Africa with low-literacy cohorts and used instructions for use with pictures and no words to see what users found intuitive. 7. Kelly says the company’s device integrates the lancet, blood collection, and reagent delivery directly into the cassette. 8. He explains that the user only needs a three-step process and can “push bleed, go” without second-guessing the sequence. 9. Kelly says the integrated product includes an interlock because one early user pressed the button too soon even after the IFU said not to. 10. He says Otomo has supplied about 7 million devices globally across different applications. 11. Kelly cites a World Health-registered HIV self-test, a FebriDex test submitted in August for CLIA waiver, and a blood pregnancy test approved in Europe and Brazil. 12. He says the FebriDex device showed greater than 99% concordance between trained and untrained users. 13. Kelly also describes a clip-on front end for manufacturers that want better usability without retooling an existing validated cassette. 14. He says the cassette can remain unchanged and still fit reader-based workflows, while revalidation becomes a subset of the original work. 15. Kelly names future assays including testosterone, thyroid, celiac, chlamydia, gonorrhea, and an active syphilis test funded by the Australian government. 16. He says a liver function test in an Australian clinical trial could reduce clinic visits from three times a week to home testing with doctor visits only when levels change. 17. Ying Chen presents EaseBio as a portable strip-based platform that combines CRISPR, biosensors, and AI for low-resource settings. 18. Chen says her background includes a Ph.D. in pediatrics, an MBA, years as a research scientist and assistant professor, and oversight of more than 1,000 CRISPR gene-editing projects. 19. The tone is interview-driven and technical, with detailed back-and-forth explanations of device design, regulatory paths, and conference impressions. 20. People interested in diagnostics, home testing, and workflow design would likely listen; listeners wanting light banter or a nontechnical conversation might skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from cc: Life Science Podcast